Structure Therapeutics initiated with a Buy at Clear Street

Clear Street analyst Kaveri Pohlman initiated coverage of Structure Therapeutics (GPCR) with a Buy rating and $61 price target The firm contends that oral formulations are poised to disrupt the diabesity market, offering efficacy and safety that rivals, if not surpasses, current standards, the analyst tells investors in a research note. Structure’s lead asset, aleniglipron, is a scalable, small-molecule oral GLP-1 inhibitor that could deliver a game-changing proof of concens with Phase 2b data expected by 2025-end, and if results match Eli Lilly’s (LLY) orforglipron and semaglutide, this could be the next major stock catalyst, the firm added.